BridgeMD
New treatment option for Acute Myeloid Leukemia
Official title Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
ClinicalTrials.gov ID: NCT06197672
What this study is testing
What is CD4CAR?
CD4CAR is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for acute myeloid leukemia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory AML. The study will evaluate safety in this subject population and also the presence of efficacy signal described by elimination of residual disease to qualify subjects for stem cell transplant.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- ≥ 12 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization.
- Diagnosis of AML that is CD4+ and must have failed standard induction/ first line treatment such as intensive induction or less intensive...
- Creatinine clearance of \> 60ml/min (or otherwise non clinically significant, per study investigator)
- alanine aminotransferase/ aspartate aminotransferase ALT/AST \< 3 x ULN
You likely can't join if
- CD4 negative AML
- Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential (see...
- Uncontrolled active infection necessitating systemic therapy.
- Active hepatitis B hb, or hepatitis C, HC, infection. Active hepatitis C is defined as the hepatitis C antibody is positive while quantitative HCV...
- people with a history of hepatitis B but have received antiviral therapy and have non-detectable viral DNA for 6 months prior to enrollment are...
- people seropositive for HBS antibodies due to hepatitis B virus vaccine with no signs or active infection (Negative HBs Ag, HBc and HBe Ags) are...
See the full eligibility criteria
Who can join
- ≥ 12 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization.
- Diagnosis of AML that is CD4+ and must have failed standard induction/ first line treatment such as intensive induction or less intensive hypomethylation and venetoclax first line. In the specific case of azacitidine...
- Creatinine clearance of \> 60ml/min (or otherwise non clinically significant, per study investigator)
- alanine aminotransferase/ aspartate aminotransferase ALT/AST \< 3 x ULN
- Bilirubin \< 2 x ULN (UPPER LIMIT OF NORMAL)
- No supplemental oxygen at rest Note: Pulmonary Function Test (PFT) only required per treating physician discretion
- Adequate cardiac function with EJECTION FRACTION, EF, of ≥50%
- Adequate venous access for apheresis and no other contraindications for leukapheresis Note: Adequate venous access means either sufficient access to a peripheral vein for collection or if venous access is insufficient...
- Confirmation of a bone marrow donor for post CD4CAR transplant to proceed to transplant if eligible post treatment.
What rules you out
- CD4 negative AML
- Pregnant or lactating women. The safety of this therapy on unborn children is not known. Female study participants of reproductive potential (see definition below) must have a negative serum or urine pregnancy test...
- Uncontrolled active infection necessitating systemic therapy.
- Active hepatitis B hb, or hepatitis C, HC, infection. Active hepatitis C is defined as the hepatitis C antibody is positive while quantitative HCV RNA results exceed the lower detection limit. Note the following people...
- people with a history of hepatitis B but have received antiviral therapy and have non-detectable viral DNA for 6 months prior to enrollment are eligible.
- people seropositive for HBS antibodies due to hepatitis B virus vaccine with no signs or active infection (Negative HBs Ag, HBc and HBe Ags) are eligible.
- people who had hepatitis C but have received antiviral therapy and show no detectable hepatitis C virus (HCV) viral RNA for 6 months are eligible.
- If hepatitis C antibody test is positive, then people must be tested for the presence of antigen by reverse transcription-polymerase chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA) negative.
- Concurrent use of systemic glucocorticoids in greater than replacement doses or steroid dependency defined in rheumatological and pulmonary diseases as uninterrupted corticosteroid intake for more than a year at a...
- Hydrocortisone 25mg/day or less
- Prednisone 10mg/day or less
- Dexamethasone 4mg or less Note: Recent or current use of inhaled glucocorticoids is not exclusionary, as this route pertains extremely minimal systemic penetration
- Any uncontrolled active medical disorder that would preclude participation as outlined in the opinion of the treating investigator and/or Principal Investigator
- HIV infection
- people who have received or will receive live vaccines within 30 days before the first experimental cell treatment. Inactivated seasonal flu vaccination is allowed.
- people with active autoimmune diseases who need systematic treatments (such as disease modifying agents, corticosteroids, and immunosuppressive drugs) during the last year. Note: Replacement therapy (thyroxine, insulin...
- people with a history of mental disorders or drug abuse that may influence treatment compliance.
- Active malignancy not related to AML that has required therapy in the last 3 years or is not in complete remission. Exceptions to this criterion include successfully treated non-metastatic basal cell or squamous cell...
- Treatment with any investigational cell/gene therapy within the past 6 months
- Treatment with any investigational anticancer agent within the past 14 days of study entry or 5 half-lives (whichever is shorter). Eligibility for Conditioning Chemotherapy:
- Specific organ function criteria for cardiac, renal, and liver function must be similar to initial inclusion values.
- Review of co-morbidities to confirm no major changes in health status (examples of major changes include heart attack, stroke, and any major trauma).
- Planned infusion does was successfully manufactured and met release criteria.
- Negative pregnancy testing (if applicable). Eligibility for CD4CAR infusion:
- Afebrile and not receiving antipyretics, and no evidence of active infection per PI discretion. If fever is attributed to underlying disease, it will not disqualify.
- Specific organ function criteria for cardiac, renal, and liver function must be similar to initial inclusion values. The following tests does not need repeated: EF if within 6 weeks of screening assessment. Note: people...
- Subject develops a respiratory infection that results in significant changes in lung imaging from baseline
- Subject's oxygenation from daily activities is compromised at baseline; or there is a significant change in oxygenation or lung imaging from baseline
- If previous history of corticosteroid chemotherapy, subject must be off all but adrenal replacement doses 3 days before the CD4CAR infusion. Exclusion Criteria: Note: A subject may still receive the CD4CAR infusion up...
- Requirement for supplemental oxygen to keep saturation greater than 95% or presence of radiographic abnormalities on a clinically indicated chest x-ray that are progressive.
- New cardiac arrhythmia not controlled with medical management.
- Hypotension requiring pressor support.
- Positive blood cultures for bacteria, fungus, or virus within 48-hours of T cell infusion.
The study team makes the final eligibility decision.
Where it's taking place
- Miami, Florida, United States
- Indianapolis, Indiana, United States
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Miami, Florida, United States; Indianapolis, Indiana, United States; Houston, Texas, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.